Geron Corporation
GERN · NASDAQ
Bulios Fair Price
$1.54
25.7% upside
Trenutna cena
$1.23
Po podatkih Bulios Fair Price je delnica GERN trenutno podcenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
O podjetju
Geron Corporation is an American biotechnology company focused on researching and developing therapeutic drugs for the treatment of various oncological diseases and other serious conditions. The company specializes in telomerase inhibition therapy, a process that targets the suppression of uncontrolled cell growth in cancerous conditions. Geron Corporation focuses on clinical trials and drug development with the potential to alleviate patient suffering and improve their quality of life. The company also has research and licensing programs for the development of new therapeutic drugs. Investing in Geron Corporation (GERN) shares may be an interesting choice for investors who follow the biotechnology industry and seek investment opportunities in a company with an innovative approach to treating serious diseases.
V vašem jeziku še ni na voljo, zato je besedilo v angleščini.
Sector
Healthcare
Industry
Biotechnology
CEO
Harout Semerjian
Employees
258
Headquarters
Foster City
Prihajajoči dogodki
Earnings
Upcoming earnings report